Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a ...

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

The company is one of the first to receive a “platform technology designation,” which could speed the review of certain gene ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

The investment bank says funding was down 57% last month, to $2.7 billion, and argues the new administration’s FDA ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.